Business
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound Docetaxel for Injection (HB1801) from CSPC as neoadjuvant treatment of breast cancer, have been
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound Docetaxel for Injection (HB1801) from CSPC as neoadjuvant treatment of breast cancer, have been selected for presentation at Late-Breaking Abstract (LBA) Oral Presentation Session of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study was led by Professor Zhimin Shao of Fudan University Shanghai Cancer Center as the principal investigator. This marks a major breakthrough for China-originated innovative therapies on the international academic stage.","length":935,"tagName":"p"},{"type":"text","content":"The ASCO Annual Meeting is the largest and most prestigious annual conference in the global oncology field. LBA Oral Presentation represents the most highly anticipated segment of the meeting, showcasing clinical research findings of the greatest clinical significance and with the strongest potential to change clinical practice. The 2026 ASCO Annual Meeting will be held from May 29, 2026 to June 2, 2026 (local time) in Chicago, the United States.","length":450,"tagName":"p","attribs":{}},{"type":"text","content":"Title: Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trialPresentation Format: Oral PresentationAbstract Number: LBA660Principal Investigator: Professor Zhimin Shao, Fudan University Shanghai Cancer CenterPresentation Time: May 30, 2026, 3:39-3:51 PM CDT","length":477,"tagName":"p","attribs":{}},{"type":"text","content":"KN026-004 is a randomized, controlled, open-label, multicenter Phase III study designed to evaluate the efficacy and safety of anbenitamab plus HB1801 ± carboplatin versus trastuzumab plus pertuzumab and docetaxel ± carboplatin as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer. The resu...